Patents by Inventor Isabelle Andre
Isabelle Andre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926851Abstract: The present invention relates to esterases, more particularly to esterase variants having improved activity and/or improved thermostability compared to the esterase of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.Type: GrantFiled: December 22, 2022Date of Patent: March 12, 2024Assignee: CARBIOSInventors: Benoît David, Isabelle Andre, Maher Ben Khaled, Sophie Duquesne, Alain Marty
-
Publication number: 20240059859Abstract: The present invention relates to novel proteases, more particularly to protease variants having improved thermostability compared to the protease of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The proteases of the invention are particularly suited to degrade polylactic acid, and material containing polylactic acid.Type: ApplicationFiled: December 21, 2021Publication date: February 22, 2024Inventors: YOUNES BOUCHIBA, ISABELLE ANDRE, SOPHIE BARBE, SOPHIE DUQUESNE
-
Publication number: 20240002423Abstract: The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.Type: ApplicationFiled: September 8, 2023Publication date: January 4, 2024Inventors: Laurence MULARD, Guillaume LE HEIGET, Zhaohu HU, Louis-Antoine BAREL, Isabelle ANDRE, Claire MOULIS, Magali REMAUD-SIMEON, Sophie BARBE, Mounir BENKOULOUCHE, Akli BEN IMEDDOURENE
-
Patent number: 11834468Abstract: The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.Type: GrantFiled: July 3, 2018Date of Patent: December 5, 2023Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Laurence Mulard, Guillaume Le Heiget, Zhaohu Hu, Louis-Antoine Barel, Isabelle Andre, Claire Moulis, Magali Remaud-Simeon, Sophie Barbe, Mounir Benkoulouche, Akli Ben Imeddourene
-
Publication number: 20230293586Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.Type: ApplicationFiled: April 6, 2023Publication date: September 21, 2023Applicants: Assistance Publique - Hopitaux de Paris, Fondation Imagine - Institut des Maladies Génétiques, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Isabelle ANDRÉ, Marina CAVAZZANA, Kuiying MA, John TCHEN, Tayebeh-Shabi SOHEILI, Ranjita Devi MOIRANGTHEM
-
Publication number: 20230212537Abstract: The present invention relates to esterases, more particularly to esterase variants having improved activity and/or improved thermostability compared to the esterase of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.Type: ApplicationFiled: December 22, 2022Publication date: July 6, 2023Inventors: BENOÎT DAVID, ISABELLE ANDRE, MAHER BEN KHALED, SOPHIE DUQUESNE, ALAIN MARTY
-
Patent number: 11692181Abstract: The present invention relates to novel esterases, more particularly to esterase variants having improved activity and/or improved thermostability compared to the esterase of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.Type: GrantFiled: July 26, 2019Date of Patent: July 4, 2023Assignee: CARBIOSInventors: Isabelle Andre, Vincent Tournier, Alexandre Gilles, Sophie Duquesne
-
Patent number: 11642376Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.Type: GrantFiled: February 11, 2021Date of Patent: May 9, 2023Assignees: Assistance Publique—Hopitaux de Paris, Fondation Imagine—Institut des Maladies Génétiques, Université de Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Isabelle André, Marina Cavazzana, Kuiying Ma, John Tchen, Tayebeh-Shabi Soheili, Ranjita Devi Moirangthem
-
Publication number: 20230135014Abstract: The present invention relates to novel esterase, more particularly to esterase variants having improved thermostability compared to the esterase of SEQ ID No 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.Type: ApplicationFiled: August 15, 2022Publication date: May 4, 2023Inventors: CHRISTOPHER TOPHAM, HÉLÈNE TEXIER, VINCENT TOURNIER, MARIE-LAURE DESROUSSEAUX, SOPHIE DUQUESNE, ISABELLE ANDRE, SOPHIE BARBE, ALAIN MARTY
-
Patent number: 11638723Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.Type: GrantFiled: February 11, 2021Date of Patent: May 2, 2023Assignees: Assistance Publique—Hopitaux de Paris, Fondation Imagine—Institut des Maladies Génétiques, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Isabelle André, Marina Cavazzana, Kuiying Ma, John Tchen, Tayebeh-Shabi Soheili, Ranjita Devi Moirangthem
-
Patent number: 11549105Abstract: The present invention relates to novel proteases, more particularly to protease variants having improved activity compared to the protease of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The proteases of the invention are particularly suited to degrade polylactic acid, and material containing polylactic acid.Type: GrantFiled: December 21, 2018Date of Patent: January 10, 2023Assignee: CARBIOSInventors: Alain Marty, Sophie Duquesne, Marie Guicherd, Marc Gueroult, Isabelle Andre
-
Patent number: 11535832Abstract: The present invention relates to esterases, more particularly to esterase variants having improved activity and/or improved themostability compared to the esterase of SEQ ID NO:1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.Type: GrantFiled: July 26, 2019Date of Patent: December 27, 2022Assignee: CARBIOSInventors: Benoît David, Isabelle Andre, Maher Ben Khaled, Sophie Duquesne, Alain Marty
-
Patent number: 11426430Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.Type: GrantFiled: September 2, 2020Date of Patent: August 30, 2022Assignees: Assistance Publique—Hopitaux de Paris, Fondation Imagine—Institut des Maladies Génétiques, UniversitéParis Cite, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Isabelle André, Marina Cavazzana, Kuiying Ma, John Tchen, Tayebeh-Shabi Soheili, Ranjita Devi Moirangthem
-
Publication number: 20220265781Abstract: The inventors have identified an autosomal dominant (AD) missense mutation in the RAC2 gene (coding for Ras-related botulinum toxin substrate 2 (RAC2)) in three Severe combined immunodeficiencies (SCID) patients whose clinical presentation overlaps with the RD SCID form but who lack AK2 mutations and deafness. Using biochemical and in vitro differentiation assays, the inventors demonstrated that the RAC2 mutation was closely related to an impairment in cell differentiation capacity and defects in cellular and mitochondrial networks. Taken as a whole, the data demonstrate that a dominant gain-of-function (GOF) mutation in the RAC2 protein's GDP/GTP binding site inhibits HSPC differentiation and leads to a severe AD form of SCID with a clinical presentation of RD. Accordingly, the results prompt to consider that introduction of the identified RAC2 mutein in the hematopoietic lineage would be suitable for inducing full ablation of hematopoiesis.Type: ApplicationFiled: July 17, 2020Publication date: August 25, 2022Inventors: Chantal LAGRESLE-PEYROU, Aurélien OLICHON, Hanem SADEK - ROCK, Isabelle ANDRE, Marina CAVAZZANA
-
Patent number: 11414651Abstract: The present invention relates to novel esterase, more particularly to esterase variants having improved thermostability compared to the esterase of SEQ ID No 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.Type: GrantFiled: March 9, 2020Date of Patent: August 16, 2022Assignee: CARBIOSInventors: Christopher Topham, Hélène Texier, Vincent Tournier, Marie-Laure Desrousseaux, Sophie Duquesne, Isabelle Andre, Sophie Barbe, Alain Marty
-
Publication number: 20220168394Abstract: Some rare and very severe autoimmune conditions are of hereditary origin such as APECED and IPEX syndrome due to altered negative selection of autoreactive T cells in the thymus or absence of regulatory T cells (Treg). Innovative strategies based on the use of regulatory T cells have been developed. The inventors have now compared 7 different experimental protocols to identify the one allowing to get the most efficacy of Treg to treat Scurfy autoimmune syndrome, a severe autoimmune model mimicking IPEX syndrome. The optimized protocol comprised a preconditioning step using cyclophosphamide and a post-conditioning step using IL-2. Thus, to present invention relates to a method for the treatment of autoimmunity in patient in need thereof comprising the steps of i) administering the patient with an amount of cyclophosphamide, ii) then engrafting the patient with an amount of the population of Treg cells, and iii) finally administering the patient with an amount of IL-2.Type: ApplicationFiled: April 22, 2020Publication date: June 2, 2022Inventors: Isabelle ANDRE, Julien ZUBER, Emmanuelle SIX, Marianne DELVILLE, Marina CAVAZZANA
-
Publication number: 20220136006Abstract: IPEX (Immune dysregulation Polyendocinopathy X linked) syndrome is a primary immunodeficience caused by mutations in the gene encoding the transcription factor forkhead box P3 (FOXP3), which leads to the loss of function of thymus-derived CD4+CD25+ regulatory T (tTreg) cells. Preclinical and clinical studies suggest that T cell gene therapy approaches designed to selectively restore the repertoire of Treg cells by transfer of wild type FOXP3 gene is a promising potential cure for IPEX. However, there is still a need for a vector that can be used efficiently for the preparation of said Treg cells. The inventors thus compared 6 different lentiviral constructs according to 4 criteria (vector titers, level of transduction of human CD4+ T cells, level of expression of FOXP3 and ?LNGFR genes, degree of correlation between both expression) and selected one construct comprising a bidirectional EFS-PGK promoter that showed remarkable efficiency.Type: ApplicationFiled: February 4, 2020Publication date: May 5, 2022Inventors: Isabelle ANDRE, Emmanuelle SIX, Florence BELLIER, Marianne DELVILLE, Mariana CAVAZZANA, Mario AMENDOLA, Axel SCHAMBACH
-
Publication number: 20220017919Abstract: IPEX (Immune dysregulation Polyendocrinopathy X linked) syndrome is a primary immunodeficiency caused by mutations in the gene encoding the transcription factor forkhead box P3 (FOXP3), which leads to the loss of function of thymus-derived CD4+CD25+ regulatory T (tTreg) cells. Preclinical and clinical studies suggest that T cell gene therapy approaches designed to selectively restore the repertoire of Treg cells by transfer of wild type FOXP3 gene is a promising potential cure for IPEX. However, there is still a need for a vector that can be used efficiently for the preparation of said Treg cells. The inventors thus compared 6 different lentiviral constructs according to 4 criteria (vector titers, level of transduction of human CD4+ T cells, level of expression of FOXP3 and ?LNGFR genes, degree of correlation between both expression) and selected one construct comprising a bidirectional PGK-EF1a promoter that showed remarkable efficiency.Type: ApplicationFiled: November 19, 2019Publication date: January 20, 2022Inventors: Isabelle ANDRE, Emmanuelle SIX, Florence BELLIER, Marianne DELVILLE, Marina CAVAZZANA, Mario AMENDOLA, Axel SCHAMBACH
-
Publication number: 20210261931Abstract: The present invention relates to novel esterase, more particularly to esterase variants having improved thermostability compared to the esterase of SEQ ID No 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.Type: ApplicationFiled: March 9, 2020Publication date: August 26, 2021Inventors: CHRISTOPHER TOPHAM, HÉLÈNE TEXIER, VINCENT TOURNIER, MARIE-LAURE DESROUSSEAUX, SOPHIE DUQUESNE, ISABELLE ANDRE, SOPHIE BARBE, ALAIN MARTY
-
Patent number: 11072784Abstract: The present invention relates to novel esterase, more particularly to esterase variants having improved activity compared to the esterase of SEQ ID No 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.Type: GrantFiled: March 16, 2020Date of Patent: July 27, 2021Assignee: CARBIOSInventors: Vincent Tournier, Hélène Texier, Marie-Laure Desrousseaux, Christopher Topham, Isabelle Andre, Sophie Barbe, Sophie Duquesne, Alain Marty